Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
July 16, 2020 Off

Banner Life Sciences Announces Commercial Launch of BAFIERTAM, a Novel Oral Fumarate Treatment for Relapsing Forms of Multiple Sclerosis

By BusinessWire

BAFIERTAM™ (monomethyl fumarate), a novel fumarate with a similar profile as Vumerity®, will be commercially available September 1, 2020 HIGH…

July 16, 2020 Off

Banner Life Sciences Announces Commercial Launch of BAFIERTAM, a Novel Oral Fumarate Treatment for Relapsing Forms of Multiple Sclerosis

By BusinessWire

BAFIERTAM™ (monomethyl fumarate), a novel fumarate with a similar profile as Vumerity®, will be commercially available September 1, 2020 HIGH…

July 16, 2020 Off

Banner Life Sciences Announces Commercial Launch of BAFIERTAM, a Novel Oral Fumarate Treatment for Relapsing Forms of Multiple Sclerosis

By BusinessWire

BAFIERTAM™ (monomethyl fumarate), a novel fumarate with a similar profile as Vumerity®, will be commercially available September 1, 2020 HIGH…

July 16, 2020 Off

PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

By BusinessWire

Recently launched Phase 2 “VANGARD” trial to assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high…

July 16, 2020 Off

PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

By BusinessWire

Recently launched Phase 2 “VANGARD” trial to assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high…

July 16, 2020 Off

PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

By BusinessWire

Recently launched Phase 2 “VANGARD” trial to assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high…

July 16, 2020 Off

PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

By BusinessWire

Recently launched Phase 2 “VANGARD” trial to assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high…

July 16, 2020 Off

Sacramento Area Biotechnology Company Providing Crucial COVID-19 Testing for Organ Donors During Pandemic

By BusinessWire

FOLSOM, Calif.–(BUSINESS WIRE)–StemExpress, a Folsom, California headquartered biotechnology company is now providing critical COVID-19 testing capabilities to Sierra Donor Services…

July 16, 2020 Off

Nexien BioPharma, Inc. Has Been Issued a U.S. Patent for the Methods and Compositions for Treating Non-Dystrophic Myotonia and Myotonic Dystrophies Types 1 and 2

By BusinessWire

The patent relates to the administration of a specific composition comprised of cannabinoids to a patient DENVER–(BUSINESS WIRE)–Nexien BioPharma, Inc.…

July 16, 2020 Off

The Oncology Institute Extends Its Reach to Serve an Additional 180,000 Patients Through New Contracts and Acquisitions

By BusinessWire

CERRITOS, Calif.–(BUSINESS WIRE)–#healthcare–The Oncology Institute of Hope and Innovation (TOI), the largest community oncology practice on the West Coast, announced…

Posts pagination

Previous 1 … 4,738 4,739 4,740 … 6,215 Next

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Rare Diseases Treatment Market Analysis and Forecast 2025-2032: A $45.8 Billion Opportunity – Complex Challenges and Unprecedented Opportunities are Emerging – ResearchAndMarkets.com

December 19, 2025 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine